Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The most important cause of mortality amongst DM2 patients is cardiovascular disease. An
early finding of cardiovascular disease in DM2 and obesity is diastolic dysfunction.
Diastolic dysfunction is an independent predictor of mortality and has been shown to improve
in patients on a low calorie diet. The improvement of diastolic function was associated with
a reduction in triglyceride accumulation in the heart and liver. A relatively new widely
prescribed therapeutic agent for DM2 patients is Liraglutide (Victoza®). Liraglutide is a
Glucagon Like Peptide - 1 homologue that improves glucose homeostasis and reduces blood
pressure and body weight. Next to the induction of weight loss, which is potentially
beneficial for cardiac function, GLP-1 therapy might have a direct advantageous effect on the
cardiovascular system. However, the effect of Liraglutide on cardiovascular function has not
been investigated yet. The investigators hypothesize that treatment of DM2 patients with
Liraglutide is associated with improvement of cardiovascular function and a reduction of
triglyceride accumulation in end-organs.